Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia
Less than 40% of patients with newly diagnosed adult immune thrombocytopenia will show spontaneous recovery within 12 months. Therefore, second-line treatments are frequently used to maintain a hemostatic platelet count or at best to cure the disease, with as few adverse effects as possible. Neverth...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2020-04-01
|
| シリーズ: | Platelets |
| 主題: | |
| オンライン･アクセス: | http://dx.doi.org/10.1080/09537104.2019.1636018 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|